All In Biotech

Drug Trial Radar · NCT05164341

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

69

Actual

Start

Dec 17, 2021

Primary completion

Jul 14, 2026

Study completion Oct 6, 2026

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Conditions

  • Partial Lipodystrophy

Interventions

  • metreleptinDrug

    Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to month 6 in HbA1c in subjects with partial lipodystrophy (PL)Time frame: 6 months
  2. Percent change from Baseline to month 6 in fasting TGs in subjects with partial lipodystrophy (PL)Time frame: 6 months

Locations

31 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • UC Davis

    Sacramento, California

  • Flourish Boca Raton

    Boca Raton, Florida

  • Emory University

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • University of Missouri

    Columbia, Missouri

  • Amryt Research Site, Endocrinology Research Associates Inc

    Columbus, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • UZ Leuven

    Leuven, Belgium

  • Universitário Walter Cantídio

    Fortaleza, Brazil

  • Insight Centro de Pesquisas

    Porto Alegre, Brazil

  • Hospital das Clinicas FMRP-USP

    Ribeirão Preto, Brazil

  • Instituto Estadual de Diabetes e Endocrinologia (IEDE-RJ)

    Rio de Janeiro, Brazil

  • Nova Scotia Health

    Halifax, Nova Scotia, Canada

  • Care Access Clinic

    Sydney, Nova Scotia, Canada

  • Hamilton General Hospital- McMaster University

    Hamilton, Ontario, Canada

  • London Health Science Centre

    London, Ontario, Canada

  • Ecogene-21

    Chicoutimi, Quebec, Canada

  • Faculty of Medicine, Universite Laval

    Québec, Quebec, Canada

  • Universidad Catolica

    Santiago, Chile

  • Hadassah University Hospital - Ein Kerem

    Jerusalem, Israel

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Radboud University Medical Centre Interne Geneeskund

    Nijmegen, Netherlands

  • Uniwersyteckie Centrum Kliniczne

    Katowice, Poland

  • SPZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • University Clinical Hospital of Santiago de Compostela/Hospital Universitario

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.